FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Vashington,	D.C.	20549	
vasilington,	D.C.	20040	

shington, D.C. 20549	9
----------------------	---

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person (Check all applicable) Clearside Biomedical, Inc. [ CLSD ] YERXA BENJAMIN R X Director 10% Owner 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify (First) (Middle) 05/15/2024 below) below) (Last) C/O CLEARSIDE BIOMEDICAL, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) 900 NORTH POINT PARKWAY, SUITE 200 Form filed by One Reporting Person Form filed by More than One Reporting Person 30005 ALPHARETTA GA Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2A. Deemed Execution Date, 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of 6. Ownership 7. Nature Date (Month/Day/Year) Transaction Securities Beneficially Form: Direct of Indirect if any Code (Instr. (D) or Indirect **Beneficial** (Month/Day/Year) 8) Owned Follo (I) (Instr. 4) (Instr. 4) Reported (A) or (D) Transaction(s) Code ν Amount Price (Instr. 3 and 4) Common Stock 05/15/2024 7,813 \$1.31 17 957 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

6. Date Exercisable and

Expiration Date

Expiration Date

Date

Exercisable

(Month/Day/Year)

**Explanation of Responses:** 

Conversion

or Exercise

Derivative

Price of

Security

1. Title of

Derivative

Security (Instr. 3)

/s/ Mark Ballantyne, Attorney- 05/15/2024 in-Fact

\*\* Signature of Reporting Person

Amount of

Underlying

Security (Instr. 3 and 4)

Amount Numbe

Shares

Securities

Derivative

Title

Date

9. Number of

derivative

Securities

Following Reported

(Instr. 4)

Transaction(s)

Owned

Beneficially

Derivative

Security (Instr. 5)

11. Nature

of Indirect

Beneficial

(Instr. 4)

Ownership

Ownership

Direct (D)

or Indirect (I) (Instr. 4)

Form:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

3A. Deemed

**Execution Date.** 

if any (Month/Day/Year)

3. Transaction

(Month/Day/Year)

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

5. Number

Derivative

Securities

Acquired

(A) or Disposed

(Instr. 3, 4

of (D)

and 5)

(A) (D)

Transaction Code (Instr.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).